Cannabis-based products for pediatric epilepsy: An updated systematic review. (February 2020)

• Record Type: Journal Article
• Authors: Elliott, Jesse; DeJean, Deirdre; Clifford, Tammy; Coyle, Doug; Potter, Beth K; Skidmore, Becky; Alexander, Christine; Repetski, Alexander E.; Shukla, Vijay; McCoy, Bláthnaid; Wells, George A.
• Is Part Of: Seizure. Volume 75(2020)
• Page Start: 18
• Page End: 22
• Publication Date: 2020-02
• Subjects: CBD cannabidiol, LSR living systematic review -- NRS non-randomized study -- RCT randomized controlled trial -- QoL quality of life -- SUDEP sudden unexpected death in epilepsy -- ER emergency room -- ROB risk of bias -- RR relative risk -- RD risk difference -- MD mean difference -- CI confidence interval; Paediatric drug-resistant epilepsy -- Cannabidiol -- Seizure -- Efficacy -- Safety -- Living systematic review; Epilepsy -- Periodicals; Epilepsy -- Periodicals; Seizures -- Periodicals; Épilepsie -- Périodiques; Electronic journals; Electronic journals; 616.853
• DOI: 10.1016/j.seizure.2019.12.006
• Languages: English
• ISSNs: 1059-1311

Abstract

Abstract: Purpose: To provide an up-to-date summary of the benefits and harms of cannabis-based products for epilepsy in children. Methods: We updated our earlier systematic review, by searching for studies published up to May 2019. We included randomized controlled trials (RCTs) and non-randomized studies (NRS) involving cannabis-based products administered to children with epilepsy. Outcomes were seizure freedom, seizure frequency, quality of life, sleep, status epilepticus, death, gastrointestinal adverse events, and emergency room visits. Results: Thirty-five studies, including four RCTs, have assessed the benefits and harms of cannabis-based products in pediatric epilepsy (12 since April 2018). All involved cannabis-based products as adjunctive treatment, and most involved cannabidiol. In the RCTs, there was no statistically significant difference between cannabidiol and placebo for seizure freedom (relative risk 6.77, 95 % confidence interval [CI] 0.36–128.38), quality of life (mean difference [MD] 0.6, 95 %CI –2.6 to 3.9), or sleep disruption (MD –0.3, 95 %CI –0.8 to 0.2). Data from both RCTs and NRS suggest that cannabidiol reduces seizure frequency and increases treatment response; however, there is an increased risk of gastrointestinal adverse events. Conclusion: Newly available evidence supports earlier findings that cannabidiol probably reduces the frequency of seizures among children with drug-resistant epilepsy. PROSPERO: CRD42018084755